Annual report
7681.TEDINET S100V0D2
Period2023-10-01 → 2024-09-30
Filed2024-12-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amends S100UYNL. Amended by S100V0EI (2024-12-25).
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.8bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥26.6bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥29.8bn | 2021-10-01 → 2022-09-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥26.3bn | 2020-10-01 → 2021-09-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥22.0bn | 2019-10-01 → 2020-09-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥178m | 2023-10-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥440m | 2022-10-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥181m | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥432m | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥710m | 2021-10-01 → 2022-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥596m | 2020-10-01 → 2021-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥207m | 2019-10-01 → 2020-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥274m | 2023-10-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥432m | 2022-10-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥136m | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥271m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥437m | 2021-10-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥391m | 2020-10-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥121m | 2019-10-01 → 2020-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥155m | 2023-10-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥286m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥10.7bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥14.7bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥13.5bn | at 2022-09-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥13.0bn | at 2021-09-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥13.4bn | at 2020-09-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.9bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥9.0bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥5.7bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.7bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.5bn | at 2022-09-30d | Cons. | Net assets |
| Net assets / equity | ¥5.2bn | at 2021-09-30d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.8bn | at 2020-09-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.6bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.5bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.5bn | at 2022-09-30d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2021-09-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.4bn | at 2020-09-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥33m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥342m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥242m | 2021-10-01 → 2022-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.3bn | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.9bn | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥101m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥82m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥50m | 2021-10-01 → 2022-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥42m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥64m | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥97m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥202m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥121m | 2021-10-01 → 2022-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥298m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥238m | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥23.09 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.12 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.3 | 2021-10-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.64 | 2020-10-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.84 | 2019-10-01 → 2020-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥22.96 | 2023-10-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥45.84 | 2022-10-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥73.84 | 2021-10-01 → 2022-09-30d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥66.11 | 2020-10-01 → 2021-09-30d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥20.62 | 2019-10-01 → 2020-09-30d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥943.51 | at 2024-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥946.33 | at 2023-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥915.42 | at 2022-09-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥855.78 | at 2021-09-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥802.93 | at 2020-09-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 52.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.9% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2022-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.8% | at 2021-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.1% | at 2020-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.4% | 2023-10-01 → 2024-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2022-10-01 → 2023-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2021-10-01 → 2022-09-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.0% | 2020-10-01 → 2021-09-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.7% | 2019-10-01 → 2020-09-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 170 | at 2024-09-30 | Cons. | Number of employees |
| Employees | 176 | at 2023-09-30 | Cons. | Number of employees |
| Employees | 175 | at 2022-09-30d | Cons. | Number of employees |
| Employees | 162 | at 2021-09-30d | Cons. | Number of employees |
| Employees | 157 | at 2020-09-30d | Cons. | Number of employees |
| Revenue | ¥17.4bn | 2023-10-01 → 2024-09-30 | Standalone | Net sales |
| Revenue | ¥24.0bn | 2022-10-01 → 2023-09-30 | Standalone | Net sales |
| Revenue | ¥27.3bn | 2021-10-01 → 2022-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥23.4bn | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥19.7bn | 2019-10-01 → 2020-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | −¥40m | 2023-10-01 → 2024-09-30 | Standalone | Operating income |
| Operating income | ¥317m | 2022-10-01 → 2023-09-30 | Standalone | Operating income |
| Ordinary income | −¥16m | 2023-10-01 → 2024-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥362m | 2022-10-01 → 2023-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥448m | 2021-10-01 → 2022-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥435m | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥234m | 2019-10-01 → 2020-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥77m | 2023-10-01 → 2024-09-30 | Standalone | Income before income taxes |
| Profit before tax | ¥362m | 2022-10-01 → 2023-09-30 | Standalone | Income before income taxes |
| Net income | ¥44m | 2023-10-01 → 2024-09-30 | Standalone | Profit loss |
| Net income | ¥269m | 2022-10-01 → 2023-09-30 | Standalone | Profit loss |
| Net income | ¥294m | 2021-10-01 → 2022-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥297m | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥194m | 2019-10-01 → 2020-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥9.5bn | at 2024-09-30 | Standalone | Assets |
| Total assets | ¥13.7bn | at 2023-09-30 | Standalone | Assets |
| Total assets | ¥12.3bn | at 2022-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.8bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.7bn | at 2020-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥4.3bn | at 2024-09-30 | Standalone | Liabilities |
| Total liabilities | ¥8.5bn | at 2023-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥5.1bn | at 2024-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.2bn | at 2023-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.0bn | at 2022-09-30d | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2021-09-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.6bn | at 2020-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.5bn | at 2024-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.7bn | at 2023-09-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥7.52 | 2023-10-01 → 2024-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.7 | 2022-10-01 → 2023-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥49.91 | 2021-10-01 → 2022-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.54 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.53 | 2019-10-01 → 2020-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥7.48 | 2023-10-01 → 2024-09-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥45.42 | 2022-10-01 → 2023-09-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥49.6 | 2021-10-01 → 2022-09-30d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥50.14 | 2020-10-01 → 2021-09-30d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥33.18 | 2019-10-01 → 2020-09-30d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥50 | 2023-10-01 → 2024-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2022-10-01 → 2023-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-10-01 → 2022-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2020-10-01 → 2021-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2019-10-01 → 2020-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥865.93 | at 2024-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥884.07 | at 2023-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥853.57 | at 2022-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥818.33 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥781.47 | at 2020-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 54.0% | at 2024-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2023-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2022-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2020-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 0.9% | 2023-10-01 → 2024-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.3% | 2022-10-01 → 2023-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2021-10-01 → 2022-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.3% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.5% | 2019-10-01 → 2020-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,967,800 | at 2024-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,960,800 | at 2023-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,960,800 | at 2022-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,960,800 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,954,400 | at 2020-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 134 | at 2024-09-30 | Standalone | Number of employees |
| Employees | 137 | at 2023-09-30 | Standalone | Number of employees |
| Employees | 134 | at 2022-09-30d | Standalone | Number of employees |
| Employees | 118 | at 2021-09-30d | Standalone | Number of employees |
| Employees | 114 | at 2020-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 57
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2023-10-01 → 2024-09-30 | −¥17,000 |
| Reconciling Itemsreconciling | segment assets | at 2024-09-30 | −¥146m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-09-30 | ¥2m |
| Food Servicereportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥3m |
| Food Servicereportable segment | employees | at 2024-09-30 | 9 pure |
| Food Servicereportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥416m |
| Food Servicereportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥416m |
| Food Servicereportable segment | segment assets | at 2024-09-30 | ¥191m |
| Food Servicereportable segment | segment profit | 2023-10-01 → 2024-09-30 | ¥14m |
| Remote Image Diagnosis Service Businessreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥7m |
| Remote Image Diagnosis Service Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥21m |
| Remote Image Diagnosis Service Businessreportable segment | employees | at 2024-09-30 | 13 pure |
| Remote Image Diagnosis Service Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥778m |
| Remote Image Diagnosis Service Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥778m |
| Remote Image Diagnosis Service Businessreportable segment | segment assets | at 2024-09-30 | ¥624m |
| Remote Image Diagnosis Service Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | ¥67m |
| Total Medical Solution Businessreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥37m |
| Total Medical Solution Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥76m |
| Total Medical Solution Businessreportable segment | employees | at 2024-09-30 | 148 pure |
| Total Medical Solution Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥18.6bn |
| Total Medical Solution Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥18.6bn |
| Total Medical Solution Businessreportable segment | segment assets | at 2024-09-30 | ¥10.0bn |
| Total Medical Solution Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | ¥95m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-10-01 → 2024-09-30 | ¥44m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-10-01 → 2024-09-30 | ¥100m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-10-01 → 2024-09-30 | ¥19.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-10-01 → 2024-09-30 | ¥19.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-09-30 | ¥10.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-10-01 → 2024-09-30 | ¥176m |
| Reconciling Itemsreconciling | depreciation | 2022-10-01 → 2023-09-30 | −¥26,000 |
| Reconciling Itemsreconciling | segment assets | at 2023-09-30 | −¥146m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2023-09-30 | ¥2m |
| Food Servicereportable segment | capex | 2022-10-01 → 2023-09-30 | ¥552,000 |
| Food Servicereportable segment | depreciation | 2022-10-01 → 2023-09-30 | ¥4m |
| Food Servicereportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥404m |
| Food Servicereportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥404m |
| Food Servicereportable segment | segment assets | at 2023-09-30 | ¥198m |
| Food Servicereportable segment | segment profit | 2022-10-01 → 2023-09-30 | ¥11m |
| Remote Image Diagnosis Service Businessreportable segment | capex | 2022-10-01 → 2023-09-30 | ¥50m |
| Remote Image Diagnosis Service Businessreportable segment | depreciation | 2022-10-01 → 2023-09-30 | ¥20m |
| Remote Image Diagnosis Service Businessreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥725m |
| Remote Image Diagnosis Service Businessreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥725m |
| Remote Image Diagnosis Service Businessreportable segment | segment assets | at 2023-09-30 | ¥545m |
| Remote Image Diagnosis Service Businessreportable segment | segment profit | 2022-10-01 → 2023-09-30 | ¥56m |
| Total Medical Solution Businessreportable segment | capex | 2022-10-01 → 2023-09-30 | ¥30m |
| Total Medical Solution Businessreportable segment | depreciation | 2022-10-01 → 2023-09-30 | ¥81m |
| Total Medical Solution Businessreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥25.5bn |
| Total Medical Solution Businessreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥25.5bn |
| Total Medical Solution Businessreportable segment | segment assets | at 2023-09-30 | ¥14.1bn |
| Total Medical Solution Businessreportable segment | segment profit | 2022-10-01 → 2023-09-30 | ¥371m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-10-01 → 2023-09-30 | ¥81m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-10-01 → 2023-09-30 | ¥104m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-10-01 → 2023-09-30 | ¥26.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-10-01 → 2023-09-30 | ¥26.6bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-09-30 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-10-01 → 2023-09-30 | ¥438m |
| Total Medical Solution Businessreportable segment | employees | at 2024-09-30 | 134 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,398
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)シップヘルスケアホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)（目的）メディカルトータルソリューション事業における安定的取引関係の構築・強化（効果）(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)ウイン・パートナーズ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)（目的）メディカルトータルソリューション事業における安定的取引関係の構築・強化（効果）(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)無(注)２ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)大塚ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)全株式を売却しました。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)無 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row2Member | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding amounts of notes and accounts receivable trade and contract assets (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding pledged assets (text) | CurrentYearInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of revenue from contracts with customers (text) | CurrentYearDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding reclassification adjustments and tax effects relating to other comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Notes leases consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes financial instruments consolidated financial statements (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |